An update on the topical and oral therapy options for treating pediatric atopic dermatitis

Expert Opin Pharmacother. 2019 Apr;20(5):621-629. doi: 10.1080/14656566.2018.1561868. Epub 2019 Jan 2.

Abstract

Introduction: Atopic dermatitis (AD) is one of the most common childhood skin disorders. Multiple mechanisms contribute to the pathology of AD and treatment approaches are directed at these processes.

Areas covered: The purpose of this review is to discuss the chemical treatment options for pediatric atopic dermatitis, including immunomodulators and small molecule inhibitors. A systematic literature search was conducted, and publications were reviewed for applicable treatment guidelines.

Expert opinion: Topical therapy is first-line for pediatric atopic dermatitis. Providers should work closely with patients and caregivers to promote the success of topical treatments. In disease refractory to topical treatments, systemic agents may be considered. Clinical trials are ongoing for the use of biologics in the treatment of pediatric AD. When choosing the most appropriate treatment, physicians should consider the drug efficacy, potential adverse effects, patient adherence, and quality of life for both patients and caregivers. Additional studies are required to determine the safest and most effective doses for systemic therapy in childhood AD.

Keywords: Atopic dermatitis; apremilast; azathioprine; calcineurin inhibitors; crisaborole; cyclosporine; dupilumab; methotrexate; mycophenolate; topical corticosteroids.

Publication types

  • Review

MeSH terms

  • Administration, Cutaneous
  • Biological Products / administration & dosage
  • Child
  • Dermatitis, Atopic / drug therapy*
  • Dermatologic Agents / administration & dosage*
  • Humans
  • Immunologic Factors / administration & dosage*
  • Medication Adherence
  • Quality of Life

Substances

  • Biological Products
  • Dermatologic Agents
  • Immunologic Factors